STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLBT
  4. [Form 4] Cellebrite DI Ltd. Insider Trading Activity

Cellebrite (NASDAQ: CLBT) CMO sells shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Cellebrite DI Ltd. (CLBT) reported that Chief Marketing Officer David Nicholas Gee sold ordinary shares in a scheduled transaction. On August 24, 2026, he sold 4,323 shares of ordinary shares at a weighted average price of $11.3605 per share, with individual trade prices ranging from $11.06 to $11.76. The sale was effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, and Gee now directly holds 135,281 shares of Cellebrite stock.

Positive

  • None.

Negative

  • None.
Insider GEE DAVID NICHOLAS
Role Chief Marketing Officer
Sold 4,323 shs ($49K)
Type Security Shares Price Value
Sale Ordinary shares, par value NIS 0.00001 F1, F2 4,323 $11.3605 $49K
Holdings After Transaction: Ordinary shares, par value NIS 0.00001 — 135,281 shares (Direct)
Footnotes (2)
  1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.06 to $11.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Shares sold 4,323 shares Ordinary shares sold by David Nicholas Gee on August 24, 2026
Weighted average sale price $11.3605 per share Average price for the 4,323 CLBT shares sold
Sale price range $11.06–$11.76 per share Range of prices at which the reported CLBT shares were sold
Shares held after transaction 135,281 shares Direct CLBT holdings of David Nicholas Gee following the sale
Rule 10b5-1 plan adoption date November 18, 2025 Date Gee adopted the trading plan used for these sales
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Ordinary shares financial
"security_title: Ordinary shares, par value NIS 0.00001"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

What insider transaction did CLBT disclose for David Nicholas Gee?
Cellebrite DI Ltd. disclosed that Chief Marketing Officer David Nicholas Gee sold 4,323 ordinary shares on August 24, 2026 in an open-market or private sale at a weighted average price of $11.3605 per share.

How many CLBT shares does David Nicholas Gee hold after this sale?
After the reported transaction, David Nicholas Gee directly holds 135,281 ordinary shares of Cellebrite DI Ltd. This figure reflects his position immediately following the August 24, 2026 sale.

At what prices were the CLBT shares sold by David Nicholas Gee?
The shares were sold at a weighted average price of $11.3605 per share. According to the disclosure, individual trades occurred at prices ranging from $11.06 to $11.76 per share, inclusive.

Was David Nicholas Gee’s CLBT share sale under a Rule 10b5-1 plan?
Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by David Nicholas Gee on November 18, 2025, indicating they were pre-arranged under that plan.

What type of security did David Nicholas Gee sell in CLBT?
David Nicholas Gee sold ordinary shares, par value NIS 0.00001, of Cellebrite DI Ltd. The transaction involved 4,323 shares in a non-derivative sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GEE DAVID NICHOLAS
(Last)(First)(Middle)
94 SHLOMO SHMELZER ROAD
(Street)
PETAH TIKVA4970602
(City)(State)(Zip)
ISRAEL
(Country)		2. Issuer Name and Ticker or Trading Symbol
Cellebrite DI Ltd. [ CLBT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Marketing Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/24/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary shares, par value NIS 0.0000108/24/2026S(1)4,323D$11.3605(2)135,281D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.06 to $11.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks:
/s/ David Nicholas Gee08/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR